Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Obesity drugs may get Medicare access under deal with White House: reports
05:29pm, Tuesday, 04'th Nov 2025
The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain Medica
Novo Nordisk Reports Earnings on Wednesday. What to Expect.
04:30pm, Tuesday, 04'th Nov 2025
The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more heated.
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb
02:45pm, Tuesday, 04'th Nov 2025
Adding more drama to Metsera Inc.'s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50.
Trump negotiating deal with Ozempic maker to sell some weight-loss drugs for $149
01:50pm, Tuesday, 04'th Nov 2025
Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
12:27pm, Tuesday, 04'th Nov 2025
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company a
Pfizer and Novo Nordisk both raise bids for Metsera
12:18pm, Tuesday, 04'th Nov 2025
CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.
Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reports
10:44am, Tuesday, 04'th Nov 2025
Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in return for coverage of products under Medicare,
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion
10:42am, Tuesday, 04'th Nov 2025
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked $8.1 billion proposal.
Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid
09:58am, Tuesday, 04'th Nov 2025
The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.
Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offer
09:40am, Tuesday, 04'th Nov 2025
Metsera said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo Nord
Should You Buy Novo Nordisk Stock Before the Huge Investor Update?
09:34am, Tuesday, 04'th Nov 2025
Novo Nordisk (NVO 1.55%) is scheduled to provide an investor update, where it is likely to discuss the latest developments on its weight loss treatments.
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
09:31am, Tuesday, 04'th Nov 2025
Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
09:20am, Tuesday, 04'th Nov 2025
Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.
Rollercoaster year for Novo Nordisk: Investors await new earnings report
03:22am, Tuesday, 04'th Nov 2025
Novo Nordisk has been on a rollercoaster this year, with stiff competition in the weight-loss drugs space. Ahead of their third quarter earnings, CNBC's Silvia Amaro takes a look at what's at stake fo
Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight
01:03am, Tuesday, 04'th Nov 2025
Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer.
